The new pill is also aimed at people who are doing well on a single-tablet regimen, including Biktarvy, and want to switch to ...

The assay’s significant limitation is its inability to assess drug resistance for integrase inhibitors, including ...

(This Aug 27 story has been republished, with no changes to text.) By Sneha S K and Kunal Das Aug 27 (Reuters) - The U.S.

As the first second-generation INSTI approved for newborns with HIV, this approval allows for a simpler, more robust antiretroviral therapy regimen than existing standard of care.

Combo could offer an alternative for those who can't take existing single-tablet regimens ...

Gilead Sciences (GILD) has been granted U.S. FDA approval for its once-daily antiviral pill, Bixlenvo as the smallest ...

The FDA approval of Bixlenvo tees up a new HIV treatment option for virologically suppressed adults, including those on ...

UNICEF estimates that in 2025, about 660 children contracted HIV and 200 died from AIDS-related causes every day, despite major global progress. Some 1.26 million children under 15 live with HIV, ...

Postdoctoral researcher Archana Joon at Albert Einstein College of Medicine studies how herpes simplex virus reshapes the ...

CNBC's Annika Kim Constantino reports on the FDA's decision to approve Gilead's daily HIV pill. Got a confidential news tip?

GLAAD reported on Thursday that most Americans say they have not seen stories about people living with HIV in the media. In ...

Despite funding cuts to HIV prevention and treatment programs and grants, Allegheny County saw the lowest number of new HIV ...